A proposed new paradigm for an anti-AIDS tolerogenic vaccine
Until now, despite 30 years of intensive work, the RV144 human immunodeficiency virus (HIV) vaccine trial initiated in 2003 remains so far the most protective vaccine prototype of all those tested (32% reduction in the infection rate three years after the vaccination) and the HIV epidemic is still s...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2022-04-01
|
| Series: | Exploration of Immunology |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/ei/Article/100346 |